Comparative Pharmacology
Head-to-head clinical analysis: MIFEPREX versus MIFEPRISTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIFEPREX versus MIFEPRISTONE.
MIFEPREX vs MIFEPRISTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mifepristone is a synthetic steroid with potent antiprogestin activity via competitive antagonism of progesterone at progesterone receptors, leading to decidual necrosis and cervical softening. It also has weak antiglucocorticoid activity.
Progesterone receptor antagonist; also has weak glucocorticoid receptor antagonist activity.
Oral administration: 600 mg single dose on day 1, followed by oral misoprostol 400 mcg 48 hours later.
Oral, 600 mg single dose followed by oral misoprostol 400 mcg 48 hours later for termination of pregnancy up to 49 days gestation.
None Documented
None Documented
Terminal elimination half-life ranges from 18 to 30 hours (mean 24 hours). In patients with hepatic impairment, half-life may be prolonged up to 60 hours.
Clinical Note
moderateMifepristone + Gatifloxacin
"Mifepristone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateMifepristone + Rosoxacin
"Mifepristone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateMifepristone + Trovafloxacin
"Mifepristone may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateMifepristone + Nalidixic acid
"Mifepristone may increase the hypoglycemic activities of Nalidixic acid."
Terminal elimination half-life is 18-30 hours (mean ~25 hours) in the elimination phase; however, a prolonged terminal half-life of up to 54 hours has been observed due to slow release from target tissues, which is clinically relevant for prolonged antiprogestogenic effects.
Primarily fecal (83%) via bile; renal excretion accounts for approximately 9% as metabolites. Unchanged drug in urine is minimal.
Primarily fecal (83%) via biliary excretion; renal excretion accounts for approximately 9% of the dose, mainly as metabolites.
Category C
Category C
Antiprogestin
Antiprogestin